Illumina has agreed to acquire SomaLogic from Standard BioTools in a deal worth up to $425 million, aiming to bolster its multiomics strategy and proteomics capabilities. This acquisition integrates SomaLogic’s DNA aptamer-based protein detection platform with Illumina’s next-generation sequencing ecosystem, enhancing biomarker discovery and disease profiling. The combined technology is expected to accelerate the commercial launch of Illumina Protein Prep, broadening access to advanced proteomic assays and consolidating Illumina's position in the growing proteomics market.